GSK (GSK) Stock Forecast & Price Target

$33.60 +0.17 (+0.51%)

(As of 12/20/2024 05:40 PM ET)

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
7

Buy
3

Based on 10 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 7 have given a hold rating, and 3 have given a strong buy rating for GSK.

Consensus Price Target

$43.25
28.72% Upside

According to the 10 analysts' twelve-month price targets for GSK, the average price target is $43.25. The highest price target for GSK is $47.00, while the lowest price target for GSK is $39.50. The average price target represents a forecasted upside of 28.72% from the current price of $33.60.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

GSK Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$43.25	$43.25	$50.00	N/A
Forecasted Upside	28.72% Upside	28.43% Upside	22.55% Upside	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

First JFK… next Elon? (Ad)

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Medical Companies	S&P 500
Consensus Rating Score	2.60	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	28.72% Upside	25,828.65% Upside	14.54% Upside
News Sentiment Rating	Neutral News See Recent GSK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Downgrade	Buy ➝ Hold
11/12/2024	Jefferies Financial Group 2 of 5 stars		Downgrade	Buy ➝ Hold	$53.00 ➝ $39.50	+8.64%
10/31/2024	Guggenheim 2 of 5 stars	S. Fernandez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/27/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/7/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hauber Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/20/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$47.00	+6.12%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Reduce
2/2/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		GBX 1,350 ➝ GBX 1,400

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:23 PM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc recently announced an increase in its quarterly dividend to $0.3928, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend yield of 4.63%, which is attractive for income-focused investors.
The stock is currently trading at $34.44, which is significantly below its 52-week high of $45.92. This may present a buying opportunity for investors looking for potential upside as the stock could rebound towards its previous highs.
Institutional interest in GSK plc remains strong, with several hedge funds increasing their stakes recently. For instance, FMR LLC boosted its holdings by 8.3%, indicating confidence in the company's future performance.
GSK plc has a solid market capitalization of $70.34 billion, which provides stability and resources for ongoing research and development in pharmaceuticals and vaccines, essential for long-term growth.
The company has received a "Moderate Buy" rating from analysts, with a consensus price target of $43.25, suggesting that there is potential for price appreciation based on analyst expectations.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

GSK plc's stock has recently experienced a decline of 2.2%, indicating potential volatility and uncertainty in the market, which could deter risk-averse investors.
The company's debt-to-equity ratio stands at 0.98, which is relatively high and may raise concerns about financial leverage and the ability to manage debt effectively.
Despite the increase in dividends, GSK plc's payout ratio is 99.35%, suggesting that the company is distributing nearly all of its earnings to shareholders, which could limit reinvestment in growth opportunities.
Insider ownership is at 10.00%, which, while not low, may indicate a lack of significant insider confidence in the company's future performance compared to other firms with higher insider ownership.
Recent trading volumes have been below average, which may indicate a lack of investor interest or confidence in the stock, potentially leading to further price declines.

GSK Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is $43.25, with a high forecast of $47.00 and a low forecast of $39.50.
: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 7 hold ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GSK shares.
: According to analysts, GSK's stock has a predicted upside of 28.72% based on their 12-month stock forecasts.
: Over the previous 90 days, GSK's stock had 3 downgrades by analysts.
: GSK has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Guggenheim, and Jefferies Financial Group in the past 90 days.
: Analysts like GSK less than other "medical" companies. The consensus rating score for GSK is 2.60 while the average consensus rating score for "medical" companies is 2.81. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

This page (NYSE:GSK) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target